This story originally ran on Aug. 17.

Agilent officials this week attributed 25 percent year-over-year growth in the company's liquid chromatography business to strong sales of its 1200 Infinity LC product line.

Agilent President and CEO Bill Sullivan said during a conference call to discuss the company's fiscal third-quarter financial results that the growth was driven by sales of the 1290 Infinity LC, which "continues to exceed expectations," and the recently introduced 1260 Infinity and 1220 Infinity systems.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.